The AHA today urged the Health Resources and Services Administration to meet the Jan. 1 effective date it has proposed for its final rule on drug ceiling prices and civil monetary penalties for manufacturers under the 340B Drug Pricing Program.
 
“We also urge that the policy changes made by the final rule, first published in January 2017, remain substantially unchanged,” AHA said today in comments on the proposed rule. 
 
Facing deadlines for responding to a lawsuit brought by the AHA, Association of American Medical Colleges, America's Essential Hospitals, 340B Health and three hospital systems, HRSA Oct. 31 proposed the regulation to change the effective and compliance date to Jan. 1.
 
In its comments, AHA also urged the agency to make pricing information available to 340B hospitals and other participating providers online through a secure website, which is required by the final rule, “available as soon as possible after the effective date.”
 

Related News Articles

Headline
The Rural Hospital Excellence in Innovation Award honors rural hospitals that are leading the way in innovative, sustainable and community-centered care. If…
Headline
AHA’s Circle of Life Award celebrates innovation in palliative and end-of-life care and seeks to provide best practices and models for the field. Programs and…
Headline
The AHA encourages hospitals and health systems that are committed to leadership and innovation in improving quality and advancing health to apply for its 2026…
Headline
The U.S. District Court for the Middle District of Tennessee June 30 denied a motion for a preliminary injunction by AbbVie in its lawsuit against the state’s…
Headline
The AHA June 27 filed an amicus brief in the U.S. District Court for the Middle District of Tennessee that defends the state’s 340B contract pharmacy law…
Chairperson's File
Public
Advocacy is a core part of the work of the AHA, protecting and sustaining what hospitals and health systems need to truly care for our communities. We often…